Laurion Capital Management LP Atreca, Inc. Transaction History

Laurion Capital Management LP

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2023 Aug 14, 2023	SELL	$0.88 - $1.22 $55,461 - $76,889	-63,024 Reduced 12.8%	429,176 $420,000
Q2 2022 Aug 15, 2022	BUY	$1.56 - $3.25 $767,832 - $1.6 Million	492,200 New	492,200 $881,000

30.6K

Ticker BCEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,876,000
Description
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-10...

Get notified when there are updates to the investment portfolio of Laurion Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Laurion Capital Management LP with notifications on news.